CAMBRIDGE, Mass., December 7, 2016 -- Mersana Therapeutics, Inc., today announced that Anna Protopapas, President and Chief Executive Officer, will present at the BMO Prescriptions for Success Healthcare Conference at the InterContinental Barclay Hotel in New York City on Wednesday, December 14, 2016, at 2:40 p.m. ET.

About Mersana Therapeutics

Mersana Therapeutics is a biotechnology company with highly differentiated and proprietary immunoconjugate platforms that allow for significantly higher drug loads, providing greater efficacy while simultaneously increasing tolerability. As a result, our platforms provide for expanded opportunities to provide meaningful clinical benefit to patients.  Our lead program, XMT1522, is in Phase I clinical trials. Our second program, XMT1536, will be entering clinical trials in the latter part of 2017.  In addition, our partners are advancing their pipeline of immunoconjugates using our platforms.

###

Media Contact

Paul Kidwell
paulkidwell@comcast.net
617-680-1088

Investors Contact
Stern Investor Relations, Inc.
Christina Tartaglia
Christina@sternir.com
(212) 362-1200